These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 22147965)

  • 21. The significance of OLGA and OLGIM staging systems in the risk assessment of gastric cancer: a systematic review and meta-analysis.
    Yue H; Shan L; Bin L
    Gastric Cancer; 2018 Jul; 21(4):579-587. PubMed ID: 29460004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adenocarcinomas at different positions at the gastro-oesophageal junction show distinct association with gastritis and gastric preneoplastic conditions.
    Bornschein J; Dingwerth A; Selgrad M; Venerito M; Stuebs P; Frauenschlaeger K; Achilleos A; Roessner A; Malfertheiner P
    Eur J Gastroenterol Hepatol; 2015 May; 27(5):492-500. PubMed ID: 25822856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. OLGA- and OLGIM-Based Staging in the Patients with Gastritis and Endoscopy Indications.
    Mansour-Ghanaei F; Joukar F; Yeganeh S; Sadeghi M; Daryakar A; Sepehrimanesh M
    Turk J Gastroenterol; 2022 Feb; 33(2):95-102. PubMed ID: 35238779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The OLGA-OLGIM staging and the interobserver agreement for gastritis and preneoplastic lesion screening: a cross-sectional study.
    Salazar BE; Pérez-Cala T; Gomez-Villegas SI; Cardona-Zapata L; Pazos-Bastidas S; Cardona-Estepa A; Vélez-Gómez DE; Justinico-Castro JA; Bernal-Cobo A; Dávila-Giraldo HA; Benítez-Guerra JC; Valencia-Cárdenas JT; Ospina EJ; Castaño-Llano R; Bravo MM; Cataño-Correa JC; Zabaleta J; Trespalacios-Rangel AA; Cock-Botero AM; Roldán-Pérez MI; Martínez A
    Virchows Arch; 2022 Apr; 480(4):759-769. PubMed ID: 35089403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk assessment of metachronous gastric cancer development using OLGA and OLGIM systems after endoscopic submucosal dissection for early gastric cancer: a long-term follow-up study.
    Na YS; Kim SG; Cho SJ
    Gastric Cancer; 2023 Mar; 26(2):298-306. PubMed ID: 36609936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autoimmune gastritis: assessment of OLGA and OLGIM staging systems.
    Ben Slama S; Ben Ghachem D; Dhaoui A; Ben Rejeb S; Jomni MT; Dougui MH; Bellil K
    Tunis Med; 2017 Apr; 95(4):262-267. PubMed ID: 29492930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. OLGA- and OLGIM-based staging of gastritis using narrow-band imaging magnifying endoscopy.
    Saka A; Yagi K; Nimura S
    Dig Endosc; 2015 Nov; 27(7):734-41. PubMed ID: 25923666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endoscopic scoring system for gastric atrophy and intestinal metaplasia: correlation with OLGA and OLGIM staging: a single-center prospective pilot study in Korea.
    Na HK; Choi KD; Park YS; Kim HJ; Ahn JY; Lee JH; Jung KW; Kim DH; Song HJ; Lee GH; Jung HY
    Scand J Gastroenterol; 2022 Sep; 57(9):1097-1104. PubMed ID: 35387540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Orientation of Gastric Biopsy Samples Improves the Inter-observer Agreement of the OLGA Staging System.
    Cotruta B; Gheorghe C; Iacob R; Dumbrava M; Radu C; Bancila I; Becheanu G
    J Gastrointestin Liver Dis; 2017 Dec; 26(4):351-356. PubMed ID: 29253048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Staging of operative link on gastritis assessment and operative link on gastric intestinal metaplasia systems for risk assessment of early gastric cancer: a case-control study.
    Huang Y; Chen J; Guo Y; Ding Z; Liang X; Zhang W; Xue H; Zhao Y; Li X; Lu H
    J Clin Pathol; 2023 Nov; ():. PubMed ID: 37989553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of Gastritis and Gastric Cancer Risk in the Chilean Population Using the OLGA System.
    Bellolio E; Riquelme I; Riffo-Campos AL; Rueda C; Ferreccio C; Villaseca M; Brebi P; Muñoz S; Araya JC
    Pathol Oncol Res; 2019 Jul; 25(3):1135-1142. PubMed ID: 30467699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HELICOBACTER PYLORI CHRONIC GASTRITIS ON PATIENTS WITH PREMALIGNANT CONDITIONS: OLGA AND OLGIM EVALUATION AND SERUM BIOMARKERS PERFORMANCE.
    Coelho MCF; Ribeiro HG; Gomes CGO; Marinho FP; Barbosa AJA; Coelho LGV
    Arq Gastroenterol; 2021; 58(1):39-47. PubMed ID: 33909795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Usefulness of OLGA and OLGIM system not only for intestinal type but also for diffuse type of gastric cancer, and no interaction among the gastric cancer risk factors.
    Yun CY; Kim N; Lee J; Lee JY; Hwang YJ; Lee HS; Yoon H; Shin CM; Park YS; Kim JW; Lee DH
    Helicobacter; 2018 Dec; 23(6):e12542. PubMed ID: 30303591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endoscopic grading of gastric intestinal metaplasia on risk assessment for early gastric neoplasia: can we replace histology assessment also in the West?
    Marcos P; Brito-Gonçalves G; Libânio D; Pita I; Castro R; Sá I; Dinis-Ribeiro M; Pimentel-Nunes P
    Gut; 2020 Oct; 69(10):1762-1768. PubMed ID: 32051208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients.
    Rugge M; Meggio A; Pravadelli C; Barbareschi M; Fassan M; Gentilini M; Zorzi M; Pretis G; Graham DY; Genta RM
    Gut; 2019 Jan; 68(1):11-17. PubMed ID: 29306868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of MTHFR C677T polymorphism with severity and localization of chronic atrophic gastritis patients without Helicobacter pylori infection: a case control study.
    Kong S; Ye F; Dang Y; Hua Y; Zhang G
    BMC Cancer; 2020 Aug; 20(1):725. PubMed ID: 32758174
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Wu M; Feng S; Qian M; Wang S; Zhang K
    Risk Manag Healthc Policy; 2022; 15():2243-2255. PubMed ID: 36475275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients.
    Rugge M; Genta RM; Fassan M; Valentini E; Coati I; Guzzinati S; Savarino E; Zorzi M; Farinati F; Malfertheiner P
    Am J Gastroenterol; 2018 Nov; 113(11):1621-1628. PubMed ID: 30333540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence and Predictors of Gastric Neoplastic Lesions in Corpus-Restricted Atrophic Gastritis: A Single-Center Cohort Study.
    Dilaghi E; Dottori L; Pivetta G; Dalla Bella M; Esposito G; Ligato I; Pilozzi E; Annibale B; Lahner E
    Am J Gastroenterol; 2023 Dec; 118(12):2157-2165. PubMed ID: 37207305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study.
    Rugge M; de Boni M; Pennelli G; de Bona M; Giacomelli L; Fassan M; Basso D; Plebani M; Graham DY
    Aliment Pharmacol Ther; 2010 May; 31(10):1104-11. PubMed ID: 20180784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.